Orbimed Advisors Llc Sells 875 Shares of Sionna Therapeutics (NASDAQ:SION) Stock

Sionna Therapeutics, Inc. (NASDAQ:SION) Director Orbimed Advisors Llc sold 875 shares of the stock in a transaction that occurred on Friday, December 19th. The shares were sold at an average price of $44.49, for a total value of $38,928.75. Following the completion of the sale, the director directly owned 3,595,011 shares of the company’s stock, valued at $159,942,039.39. This represents a 0.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Orbimed Advisors Llc also recently made the following trade(s):

• On Thursday, December 18th, Orbimed Advisors Llc sold 100 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.49, for a total transaction of $4,449.00.
• On Wednesday, December 17th, Orbimed Advisors Llc sold 900 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.50, for a total transaction of $40,050.00.
• On Wednesday, November 26th, Orbimed Advisors Llc sold 1,600 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.49, for a total transaction of $71,184.00.
• On Tuesday, November 25th, Orbimed Advisors Llc sold 11,890 shares of Sionna Therapeutics stock. The shares were sold at an average price of $44.60, for a total transaction of $530,294.00.
• On Monday, November 24th, Orbimed Advisors Llc sold 94,583 shares of Sionna Therapeutics stock. The stock was sold at an average price of $44.54, for a total value of $4,212,726.82.

Sionna Therapeutics Stock Down 4.2%

Shares of SION opened at $42.37 on Friday. The stock’s 50-day moving average price is $38.80 and its 200 day moving average price is $27.34. The firm has a market capitalization of $1.89 billion and a price-to-earnings ratio of -8.70. Sionna Therapeutics, Inc. has a 12-month low of $7.26 and a 12-month high of $45.00.

Sionna Therapeutics (NASDAQ:SION) last announced its quarterly earnings data on Wednesday, November 5th. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.06.

Sionna Therapeutics News Roundup

Here are the key news stories impacting Sionna Therapeutics this week:

• Positive Sentiment: Senior insiders and institutional holders still retain very large stakes (reported holdings ~3.596M shares each, valued ~ $160M), which signals continued alignment with long‑term performance and limits the risk of a meaningful shift in control. SEC filing
• Negative Sentiment: Director Peter A. Thompson sold a total of 1,875 SION shares across Dec. 17–19 at an average price ~ $44.49–44.50 (proceeds ≈ $83.4k). Each sale is small relative to his stake (ownership dipped ~0.03%), but the filings can prompt negative short‑term sentiment. SEC filing
• Negative Sentiment: OrbiMed Advisors LLC (reported as a director-level holder) executed the same pattern of sales (875, 100 and 900 shares on Dec. 17–19) at similar prices, reducing its position by ~0.02–0.03%. Like the individual sales, the absolute size is small versus the owner’s remaining stake but likely contributes to today’s downside pressure. SEC filing

Analyst Upgrades and Downgrades

SION has been the subject of a number of recent research reports. Raymond James Financial restated a “strong-buy” rating on shares of Sionna Therapeutics in a research note on Wednesday, November 5th. Royal Bank Of Canada reissued an “underperform” rating and issued a $24.00 price target on shares of Sionna Therapeutics in a research report on Monday, December 1st. Jones Trading started coverage on shares of Sionna Therapeutics in a research note on Monday, September 8th. They set a “buy” rating and a $46.00 price target for the company. BTIG Research assumed coverage on Sionna Therapeutics in a research note on Wednesday, November 19th. They issued a “buy” rating and a $50.00 price objective on the stock. Finally, Wall Street Zen upgraded Sionna Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, December 13th. Two analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat.com, Sionna Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $40.33.

Institutional Trading of Sionna Therapeutics

Large investors have recently added to or reduced their stakes in the company. Bank of America Corp DE increased its holdings in shares of Sionna Therapeutics by 8.8% during the third quarter. Bank of America Corp DE now owns 6,541 shares of the company’s stock worth $192,000 after buying an additional 529 shares in the last quarter. BNP Paribas Financial Markets grew its position in Sionna Therapeutics by 35.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 2,380 shares of the company’s stock worth $70,000 after acquiring an additional 619 shares during the last quarter. Russell Investments Group Ltd. acquired a new stake in Sionna Therapeutics during the 3rd quarter valued at $30,000. Police & Firemen s Retirement System of New Jersey bought a new position in Sionna Therapeutics in the 2nd quarter valued at $45,000. Finally, The Manufacturers Life Insurance Company raised its position in Sionna Therapeutics by 13.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 38,038 shares of the company’s stock valued at $660,000 after purchasing an additional 4,489 shares during the last quarter.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.